Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS

Table of Contents

March 01, 2005; Volume 74,

Mechanism of Action of Tumor Necrosis Factor Antagonists

  • You have access
    Mechanism of action of tumor necrosis factor antagonists. Proceedings of the Canadian expert roundtable meeting, Banff, Canada, November 28-30, 2003.
    The Journal of Rheumatology Supplement March 1 2005, 74 1-47;
  • You have access
    Differentiating the efficacy of tumor necrosis factor inhibitors.
    Boulos Haraoui
    The Journal of Rheumatology Supplement March 1 2005, 74 3-7;
  • You have access
    Safety of biologic therapies--an update.
    Edward C Keystone
    The Journal of Rheumatology Supplement March 1 2005, 74 8-12;
  • You have access
    Clinical pharmacokinetics of tumor necrosis factor antagonists.
    Ivan Nestorov
    The Journal of Rheumatology Supplement March 1 2005, 74 13-18;
  • You have access
    Apoptosis in the regulation of immune responses.
    Michael J Pinkoski and Douglas R Green
    The Journal of Rheumatology Supplement March 1 2005, 74 19-25;
  • You have access
    Infliximab induced T lymphocyte apoptosis in Crohn's disease.
    Jan van den Brande, Daan W Hommes and Maikel P Peppelenbosch
    The Journal of Rheumatology Supplement March 1 2005, 74 26-30;
  • You have access
    Effects of infliximab treatment on rheumatoid synovial tissue.
    Paul P Tak
    The Journal of Rheumatology Supplement March 1 2005, 74 31-34;
  • You have access
    Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
    Stefan Ehlers
    The Journal of Rheumatology Supplement March 1 2005, 74 35-39;
  • You have access
    Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
    Charles A Dinarello
    The Journal of Rheumatology Supplement March 1 2005, 74 40-47;
Back to top
PreviousNext

In this issue

The Journal of Rheumatology Supplement
Vol. 74
1 Mar 2005
  • Table of Contents
  • Index by Author
  • Most Read
  • ​ Editor's Picks
  • E-letters
Loading
  • Effects of Bedtime Very Low Dose Cyclobenzaprine on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome: A Double-blind Randomized Placebo-controlled Study
  • Extravascular Necrotizing Granuloma: A Diagnostic Clue for Eosinophilic Granulomatosis With Polyangiitis
  • Immunoglobulin A Vasculitis Following COVID-19: A French Multicenter Case Series
  • Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
  • Melorheostosis or “Dripping Candle Wax” Bone Disease
More...

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire